TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8396091

Group type: EXPERIMENTAL
Intervention: Single oral-dose of 1 g azithromycin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Seven-day course of 100 mg doxycycline twice-daily
Number of subjects: 120
Study: 3098194

Group type: EXPERIMENTAL
Intervention: sodium aurothiomalate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: auranofin
Number of subjects: 90

Group type: COMPARATOR
Intervention: auranofin placebo
Number of subjects: 90
Study: 29324708

Group type: EXPERIMENTAL
Intervention: Signal processing procedure using Golay complementary waveforms with Binomial Design algorithm and one of three proposed waveform transmission ordering algorithms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Binomial Design algorithm
Number of subjects: 0
Study: 27355509

Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) diagnostic technology using Alere q platform for HIV DNA PCR testing
Number of subjects: 2867

Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned but implied)
Number of subjects: 2867
Study: 24405797

Group type: EXPERIMENTAL
Intervention: 100 mcg buccal misoprostol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 200 mcg buccal misoprostol
Number of subjects: 153
Study: 22880629

Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked response (BAER) in NICU term neonates
Number of subjects: 55

Group type: COMPARATOR
Intervention: Normal term controls
Number of subjects: 55
Study: 20389255

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 100 mg eq.
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 50 mg eq.
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 18992700

Group type: EXPERIMENTAL
Intervention: Levodopa medication withdrawal (experimental group)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Continued levodopa medication (control group)
Number of subjects: 11
Study: 15877999

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg/day for 4 months)
Number of subjects: 17
Study: 12373663

Group type: EXPERIMENTAL
Intervention: Levetiracetam (1,000 to 4,000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11072394

Group type: EXPERIMENTAL
Intervention: Smoking abstinence group (n = 16)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continued smoking group (n = 5)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 8833936

Group type: EXPERIMENTAL
Intervention: Chronic active hepatitis
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Decompensated liver cirrhosis
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Liver cirrhosis complicated by hepatocellular carcinoma
Number of subjects: 43

Group type: COMPARATOR
Intervention: Compensated liver cirrhosis
Number of subjects: 43
Study: 2205544

Group type: EXPERIMENTAL
Intervention: Ophthalmic rod (OR) with tropicamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ophthalmic rod (OR) with oxybuprocaine HCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ophthalmic rod (OR) with fluorescein sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eyedrops (control)
Number of subjects: 0
Study: 7253054

Group type: EXPERIMENTAL
Intervention: Open technique at the infraumbilical ring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed technique of diagnostic peritoneal lavage
Number of subjects: 0
Study: 6507951

Group type: EXPERIMENTAL
Intervention: methylprednisolone 125 mg every 6 hours
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: methylprednisolone 60 mg every 6 hours
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: hydrocortisone 100 mg every 6 hours
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: higher dose glucocorticoid therapy
Number of subjects: 14
Study: 31664121

Group type: EXPERIMENTAL
Intervention: Caesarean Section (CS)
Number of subjects: 30524

Group type: COMPARATOR
Intervention: Vaginal Birth (VB)
Number of subjects: 30524
Study: 26948466

Group type: COMPARATOR
Intervention: Central vein control (CVC)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Central vein (CV)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ascending aorta (AA)
Number of subjects: 95
Study: 25361841

Group type: EXPERIMENTAL
Intervention: CCBT programme (Stressbusters)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accessing selected websites providing information about low mood/depression (Control)
Number of subjects: 0
Study: 22180125

Group type: EXPERIMENTAL
Intervention: Therapeutic group by teleconference
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20592128

Group type: EXPERIMENTAL
Intervention: rGH and neridronate (group Bp+rGH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: neridronate alone (group Bp)
Number of subjects: 30
Study: 18801505

Group type: EXPERIMENTAL
Intervention: 200 mg degarelix followed by monthly injections of 60 mg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 200 mg degarelix followed by monthly injections of 80 mg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Degarelix treatment
Number of subjects: 127
Study: 15695129

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg plus fenofibrate 160 mg (combination therapy)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Simvastatin 20 mg (monotherapy)
Number of subjects: 618
Study: 12061948

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 grams daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no creatine supplementation)
Number of subjects: 27
Study: 10822754

Group type: EXPERIMENTAL
Intervention: Weinreb's criteria for classifying blood volume
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Corrected venous haematocrit (CVH)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Blood volume analysis using direct measurement of cell volume (CV)
Number of subjects: 30
Study: 7749823

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (equivalent to two drinks per day)
Number of subjects: 34
Study: 2135208

Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.05 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg oral dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 20
Study: 7433978

Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31589610

Group type: EXPERIMENTAL
Intervention: Trichiasis surgery (bilamellar tarsal rotation procedure or posterior lamellar rotation procedure)
Number of subjects: 6747
Study: 28215759

Group type: EXPERIMENTAL
Intervention: Synbiotic (Bifidobacterium longum bv. infantis CCUG 52486 combined with gluco-oligosaccharide)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: CMV seropositivity
Number of subjects: 112

Group type: COMPARATOR
Intervention: Synbiotic
Number of subjects: 112
Study: 27424812

Group type: EXPERIMENTAL
Intervention: Early ART (started at enrollment with CD4+ count 350 to 550 cells/mm³)
Number of subjects: 1763

Group type: COMPARATOR
Intervention: Delayed ART (started after CD4+ counts fell below 250 cells/mm³ or upon AIDS-defining illness)
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Both groups (early and delayed ART)
Number of subjects: 1763
Study: 25122422

Group type: EXPERIMENTAL
Intervention: IHC (Immunohistochemistry) using 5A4, ALK1, or D5F3 antibodies; optimized protocols were used after initial results.
Number of subjects: 411

Group type: COMPARATOR
Intervention: FISH (Fluorescence in situ hybridization) using Vysis' ALK break-apart FISH kit; protocols were standardized across 12 centers.
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: IHC (Immunohistochemistry) after optimization.
Number of subjects: 411
Study: 22266899

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.2% ropivacaine at 4 mL/hr for 48 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.2% ropivacaine
Number of subjects: 40
Study: 20122035

Group type: EXPERIMENTAL
Intervention: Recent practice-changing breast cancer updates relevant to older patients
Number of subjects: 0
Study: 17160548

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 15724724

Group type: EXPERIMENTAL
Intervention: PspA vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strains from SCD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strains from non-SCD patients
Number of subjects: 0
Study: 11157716

Group type: EXPERIMENTAL
Intervention: GH-deficient nontreated patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: GH-treated patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 17
Study: 9236442

Group type: EXPERIMENTAL
Intervention: Low-energy electrical cardioversion (biphasic shock, 3/3 ms, synchronized to R wave, starting at 60 V, increased in 40-V steps up to 400 V)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-energy electrical cardioversion
Number of subjects: 42
Study: 8477412

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-40 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3478996

Group type: EXPERIMENTAL
Intervention: Aspirin 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31809262

Group type: EXPERIMENTAL
Intervention: Hypnosis (Experimental Group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60
Study: 26988693

Group type: EXPERIMENTAL
Intervention: Probiotics (multi-strain microbial cell preparation)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 25557387

Group type: EXPERIMENTAL
Intervention: Balance training for 8 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 23828292

Group type: EXPERIMENTAL
Intervention: Healthy exercise (HE)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MetS exercise (ME)
Number of subjects: 42

Group type: COMPARATOR
Intervention: MetS control (MC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy control (HC)
Number of subjects: 42
Study: 20932706

Group type: EXPERIMENTAL
Intervention: Rotating platform (RP) total knee arthroplasty
Number of subjects: 69

Group type: COMPARATOR
Intervention: Fixed-bearing (FB) total knee arthroplasty
Number of subjects: 69
Study: 19118696

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg or 0.5 mg)
Number of subjects: 423

Group type: COMPARATOR
Intervention: PDT
Number of subjects: 423
Study: 16409564

Group type: EXPERIMENTAL
Intervention: Tablet dispenser (TD)
Number of subjects: 2296

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 2296
Study: 15223446

Group type: EXPERIMENTAL
Intervention: Bronchoscopy simulator training (PreOp flexible bronchoscopic simulator, Immersion Medical, Gaithersburg, MD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No simulator training (Control group)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bronchoscopy simulator training
Number of subjects: 13
Study: 11480712

Group type: EXPERIMENTAL
Intervention: Thin-layer cytology
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional smear
Number of subjects: 500
Study: 8829027

Group type: EXPERIMENTAL
Intervention: ondansetron (8 mg BID for up to 3 days)
Number of subjects: 133

Group type: COMPARATOR
Intervention: prochlorperazine (10 mg BID for up to 3 days)
Number of subjects: 133
Study: 1390410

Group type: COMPARATOR
Intervention: Interrupted Mersilene sutures
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Single adjustable running Mersilene suture
Number of subjects: 68
Study: 2413835

Group type: EXPERIMENTAL
Intervention: High dose PVB (cis-platinum 20 mg/m2 days 1-5 every 3 weeks for four courses, bleomycin 30 mg weekly for 12 weeks, vinblastine 0.20 mg/kg on days 1 and 2 every 3 weeks for four courses)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Low dose PVB (cis-platinum 20 mg/m2 days 1-5 every 3 weeks for four courses, bleomycin 30 mg weekly for 12 weeks, vinblastine 0.15 mg/kg on days 1 and 2 every 3 weeks for four courses)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (cis-platinum and vinblastine for 1 year)
Number of subjects: 228

Group type: COMPARATOR
Intervention: No further chemotherapy
Number of subjects: 228
Study: 31671258

Group type: EXPERIMENTAL
Intervention: PCI (Percutaneous Coronary Intervention)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 1000
Study: 30184103

Group type: EXPERIMENTAL
Intervention: Infocalc-2000
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Negative control with randomly selected markers
Number of subjects: 2000
Study: 26745225

Group type: EXPERIMENTAL
Intervention: Myofascial release therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 59
Study: 24108668

Group type: EXPERIMENTAL
Intervention: Everolimus (30, 50, or 70 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m(2) loading, 250 mg/m(2) maintenance)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: DCE-MRI
Number of subjects: 29
Study: 22538694

Group type: EXPERIMENTAL
Intervention: LINX® Reflux Management System
Number of subjects: 44
Study: 19915181

Group type: EXPERIMENTAL
Intervention: Loxapine aerosol (0.625, 1.25, 2.5, 5.0, or 10 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Loxapine aerosol
Number of subjects: 50
Study: 18399737

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic group psychotherapy
Number of subjects: 18
Study: 15800093

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12521318

Group type: EXPERIMENTAL
Intervention: Lingual nerve protection during lower third molar germectomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: No lingual nerve protection during lower third molar germectomy
Number of subjects: 300
Study: 9841829

Group type: EXPERIMENTAL
Intervention: Oral, killed enterotoxigenic Escherichia coli (ETEC) plus cholera toxin B subunit vaccine
Number of subjects: 202
Study: 7492157

Group type: EXPERIMENTAL
Intervention: Hydrolysed whey formula
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amino acid formula
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 40
Study: 1347204

Group type: EXPERIMENTAL
Intervention: Pipecuronium 0.06 mg.kg-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vecuronium 0.015 mg.kg-1
Number of subjects: 0
Study: 3922823

Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg twice a day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: astemizole 10 mg once a day
Number of subjects: 47

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study: 29986529

Group type: EXPERIMENTAL
Intervention: Cube sizes of vegetable hash and chicken (0.5, 1.0, and 1.5 cm³) in Study 1 (n = 19)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mashed potatoes and mincemeat compared to whole potatoes and meatballs in Study 2 (n = 18)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Meals served at lunch time (11:00-13:00) compared to identical meals served at dinner time (17:00-19:00) in Study 3 (n = 29)
Number of subjects: 66
Study: 28159846

Group type: EXPERIMENTAL
Intervention: Standardised CHM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Individualised CHM
Number of subjects: 40
Study: 24881281

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream, applied twice a day for 4 weeks
Number of subjects: 138

Group type: COMPARATOR
Intervention: Hydrocortisone 1% cream, applied twice a day for 4 weeks
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 138

Group type: COMPARATOR
Intervention: Hydrocortisone 1% cream
Number of subjects: 138
Study: 21214918

Group type: EXPERIMENTAL
Intervention: Patient-centred, structured pharmaceutical care process
Number of subjects: 14200

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 14200
Study: 19324304

Group type: EXPERIMENTAL
Intervention: ICD treatment
Number of subjects: 655
Study: 17315118

Group type: EXPERIMENTAL
Intervention: Telemetric body weight monitoring (TBWM) with weekly reports of weight changes and alarms for IWG greater than 0.75 kg/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no TBWM)
Number of subjects: 120
Study: 15285314

Group type: EXPERIMENTAL
Intervention: IV tramadol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IV fentanyl
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural tramadol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine + fentanyl combination
Number of subjects: 80
Study: 11574041

Group type: EXPERIMENTAL
Intervention: Children with severe closed-head injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children with mild head injury
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 0
Study: 9055897

Group type: EXPERIMENTAL
Intervention: 30% glucose solution (1 ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 10% glucose solution
Number of subjects: 120

Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 120
Study: 8436151

Group type: EXPERIMENTAL
Intervention: Nicorandil 144 micrograms.kg‐1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nicorandil 200 micrograms.kg‐1
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nicorandil (various doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 48
Study: 3946953

Group type: COMPARATOR
Intervention: Free-care group
Number of subjects: 3539

Group type: EXPERIMENTAL
Intervention: Cost-sharing group
Number of subjects: 3539

Group type: EXPERIMENTAL
Intervention: Cost-sharing group (low socioeconomic status, poor health)
Number of subjects: 3539

Group type: COMPARATOR
Intervention: Free-care group (low socioeconomic status, poor health)
Number of subjects: 3539
Study: 30454669

Group type: EXPERIMENTAL
Intervention: Financial incentives up to $60 per participant and nicotine patches
Number of subjects: 2452000

Group type: COMPARATOR
Intervention: Usual care plus nicotine patches
Number of subjects: 2452000
Study: 28076508

Group type: EXPERIMENTAL
Intervention: Swing mesh (n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Modified Kugel mesh (n=60)
Number of subjects: 120
Study: 24885220

Group type: EXPERIMENTAL
Intervention: Combination probiotic agent (Lactobacillus rhamnosus and L. helveticus) for 5 days
Number of subjects: 886

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 886
Study: 21682949

Group type: EXPERIMENTAL
Intervention: Somatic depressive symptom dimension at 12 months post-MI
Number of subjects: 2442

Group type: EXPERIMENTAL
Intervention: Cognitive depressive symptom dimension
Number of subjects: 2442
Study: 20231198

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 3 mg/kg q8w
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 3 mg/kg q8w, with dose escalation to 5 mg/kg if target not met
Number of subjects: 76
Study: 18779287

Group type: EXPERIMENTAL
Intervention: 1800 mg/d EPA+DHA
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: 400 mg/d EPA+DHA
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 15766995

Group type: EXPERIMENTAL
Intervention: Intensified blood-pressure control (systolic/diastolic <130/80 mm Hg)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Conventional blood-pressure control (diastolic <90 mm Hg)
Number of subjects: 338
Study: 12001120

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin and 5-fluorouracil) followed by radiotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 80
Study: 10494606

Group type: EXPERIMENTAL
Intervention: IFN alpha 2a (6 MU, thrice weekly)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Ribavirin (14 mg/kg per day) in combination with IFN alpha 2a
Number of subjects: 169
Study: 8967579

Group type: EXPERIMENTAL
Intervention: Antibiotic bonded catheters (vancomycin 1 g in 10 ml of water)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Plain catheters (control group)
Number of subjects: 110
Study: 1961962

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 20
Study: 6118333

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oxazepam
Number of subjects: 69
Study: 31369771

Group type: EXPERIMENTAL
Intervention: Intralesional injection of bivalent HPV vaccine (0.1 to 0.3 mL) at 2-week intervals until complete clearance or for a maximum of 6 sessions
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intramuscular injection of bivalent HPV vaccine at 0, 1, and 6 months or until complete clearance of warts
Number of subjects: 44
Study: 31839083

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ESPB with 20 ml of 0.5% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wound infiltration with 20 ml of 0.5% ropivacaine
Number of subjects: 60
Study: 28750676

Group type: EXPERIMENTAL
Intervention: Bespoke training session for midwifery teams on membrane sweeping
Number of subjects: 2787
Study: 26166532

Group type: EXPERIMENTAL
Intervention: N2O inhalation (35%-50%)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.50-0.75 mg/kg)
Number of subjects: 67
Study: 23334103

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT) - repeated administration prior to encoding and retrieval
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT) - single administration prior to encoding
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 80
Study: 21851876

Group type: EXPERIMENTAL
Intervention: Carperitide infusion (hANP)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (no carperitide)
Number of subjects: 303